Determinants of platelet activation in Alzheimer's disease

Neurobiology of Aging

Volumn 28, Issue 3, 2007, Pages 336-342

  Ciabattoni, Giovanni ^a   Porreca, Ettore ^a   Di Febbo, Concetta ^a   Di Iorio, Angelo ^a   Paganelli, Roberto ^a   Bucciarelli, Tonino ^a   Pescara, Lea ^a   Del Re, Letizia ^b   Giusti, Cinzia ^b   Falco, Angela ^a   Sau, Antonella ^a   Patrono, Carlo ^c   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Ospedale Civile di Pescara   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Alzheimer's disease; Inflammation; Lipid peroxidation; Oxidative stress; Platelet activation

Indexed keywords

11 OXOTHROMBOXANE B2; 8 ISOPROSTAGLANDIN F2 ALPHA; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; C REACTIVE PROTEIN; CREATININE; INTERLEUKIN 6; ISOPROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

AGED; ALZHEIMER DISEASE; ARTICLE; BIOSYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; LOW DRUG DOSE; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; URINE LEVEL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ASPIRIN; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-SECTIONAL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LACTONES; LOGISTIC MODELS; MALE; ODDS RATIO; PLATELET ACTIVATION; RADIOIMMUNOASSAY; SULFONES; THROMBOXANE B2; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN E;

EID: 33846594266     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2005.12.011     Document Type: Article

References (47)

1. Borroni B., Akkawi N., Martini G., Colciaghi F., Prometti P., Rozzini L., et al. Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci 204 (2002) 189-193
2. Casserly I., and Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363 (2004) 1139-1146
3. 2 formation in the human circulation. Proc Natl Acad Sci USA 83 (1986) 5861-5865
4. 2 in man. Biochim Biophys Acta 992 (1989) 66-70
5. 2 in human plasma and urine. Biochim Biophys Acta 918 (1987) 293-297
6. Davì G., Catalano I., Averna M., Notarbartolo A., Strano A., Ciabattoni G., et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322 (1990) 1769-1774
7. Davì G., Averna M., Catalano I., Barbagallo C., Ganci A., Notarbartolo A., et al. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85 (1992) 1792-1798
8. 2-isoprostane biosynthesis in man. Chem Phys Lipids 128 (2004) 149-163
9. de la Torre J.C. Alzheimer's disease as a vascular disorder: nosological evidence. Stroke 33 (2002) 1152-1162
10. Di Minno G., Davì G., Margaglione M., Cirillo F., Grandone E., Ciabattoni G., et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 92 (1993) 1400-1406
11. 2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radic Biol Med 27 (1999) 463-469
12. FitzGerald G.A., Oates J.A., Hawiger J., Maas R.L., Roberts II L.J., Lawson J.A., et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71 (1983) 676-688
13. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345 (2001) 433-442
14. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
15. Hansson G.K., Libby P., Schonbeck U., and Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91 (2002) 281-291
16. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., et al. Stroke and the risk of Alzheimer disease. Arch Neurol 60 (2003) 1707-1712
17. Huo Y., and Ley K.F. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med 14 (2004) 18-22
18. Jones R.W. Inflammation and Alzheimer's disease. Lancet 358 (2001) 455-461
19. 2 in the human circulation. Anal Biochem 155 (1986) 198-205
20. Ledue T.B., Weiner D.L., Sipe J.D., Poulin S.E., Collins M.F., and Rifai N. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35 (1998) 745-753
21. Lee B.L., Chua S.C., Ong H.Y., and Ong C.N. High-performance liquid chromatographic method for routine determination of Vitamins A and E and beta-carotene in plasma. J Chromatogr 581 (1992) 41-47
22. Li Q.X., Berndt M.C., Bush A.I., Rumble B., Mackenzie I., Friedhuber A., et al. Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet. Blood 84 (1994) 133-142
23. Lombardi V.R., Garcia M., Rey L., and Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J Neuroimmunol 97 (1999) 163-171
24. 2 and prostacyclin in cigarette smokers. Circulation 112 (2005) 1024-1029
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
26. Montine K.S., Quinn J.F., Zhang J., Fessel J.P., Roberts II L.J., Morrow J.D., et al. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128 (2004) 117-124
27. 4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol 52 (2002) 175-179
28. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 87 (1990) 9383-9387
29. 2 synthase activity in platelet free human monocytes. Biochim Biophys Acta 1215 (1994) 285-290
30. Patrignani P., Filabozzi P., and Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69 (1982) 1366-1372
31. 2-isoprostane formation. Br J Pharmacol 118 (1996) 1285-1293
32. Patrono C., Davì G., and Ciabattoni G. Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. Trends Cardiovasc Med 2 (1992) 15-20
33. Patrono C., Garcia Rodriguez L.A., Landolfi R., and Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353 (2005) 2373-2383
34. Patrono C., and FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17 (1997) 2309-2315
35. 2α. J Biol Chem 270 (1995) 9800-9808
36. 2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation. FASEB J 12 (1998) 1777-1784
37. Praticò D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., and FitzGerald G.A. Increased 8, 12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 48 (2000) 809-812
38. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., et al. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 99 (2002) 7634-7639
39. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336 (1997) 1216-1222
40. Skovronsky D.M., Lee V.M., and Praticò D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 276 (2001) 17036-17043
41. Tedgui A., and Mallat Z. Platelets in atherosclerosis: a new role for beta-amyloid peptide beyond Alzheimer's disease. Circ Res 90 (2002) 1145-1146
42. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
43. van Kooten F., Ciabattoni G., Koudstaal P.J., Grobbee D.E., Kluft C., and Patrono C. Increased thromboxane biosynthesis is associated with poststroke dementia. Stroke 30 (1999) 1542-1547
44. 2-isoprostanes levels are increased in Alzheimer's disease: evidence of increased oxidative stress in vivo. Alzheimers Rep 2 (1999) 277-282
45. 2 excretion in man. J Pharmacol Exp Ther 275 (1995) 94-100
46. Yamaguchi H., Yamazaki T., Lemere C.A., Frosch M.P., and Selkoe D.J. Beta amyloid is focally deposited within the outer basement membrane in the amyloid angiopathy of Alzheimer's disease. An immunoelectron microscopic study. Am J Pathol 141 (1992) 249-259
47. Zubenko G.S., Winwood E., Jacobs B., Teply I., Stiffler J.S., Hughes III H.B., et al. Prospective study of risk factors for Alzheimer's disease: results at 7.5 years. Am J Psychiat 156 (1999) 50-57